TY - JOUR
T1 - Multicenter, randomized study comparing efficacy and safety of oral levofloxacin and cefaclor in treatment of acute bacterial exacerbations of chronic bronchitis
AU - Habib, Michael P.
AU - Gentry, Layne O.
AU - Rodriguez-Gomez, Guillermo
AU - Morowitz, William
AU - Polak, Elaine
AU - Rae, Jena K.
AU - Morgan, Nancy S.
AU - Williams, R. Rex
PY - 1998/2
Y1 - 1998/2
N2 - This prospective, multicenter randomized trial compared the safety and efficacy of 5-7 of therapy with oral levofloxacin (500 mg qd) with 7-10 days of therapy with cefaclor (250 mg tid) in the treatment of patients with acute bacterial exacerbations of chronic bronchitis (ABECB). One hundred ninety- two patients were evaluable of microbiologic efficacy. The overall bacteriologic eradication rates by pathogen were 94% and 87% for levoflaxacin and cefaclor, respectively. Levofloxacin eradicated 100% of Haemophilus influenzae, 95% of Moraxella catarrhalis, and 90% of Streptococcus pneumoniae organisms vs. 71%, 100%, and 86%, respectively, for cefaclor. Clinical success was observed in 92% of the patients in both groups. Drug-related adverse events were reported in 7% and 5% of patients, respectively, with gastrointestinal adverse events being the most common. These results indicate that once a day dosing of levofloxacin (500 mgg) is as effective and well tolerated as three-times-per-day dosing of cefaclor (250 mgg) in the treatment of patients with ABECB.
AB - This prospective, multicenter randomized trial compared the safety and efficacy of 5-7 of therapy with oral levofloxacin (500 mg qd) with 7-10 days of therapy with cefaclor (250 mg tid) in the treatment of patients with acute bacterial exacerbations of chronic bronchitis (ABECB). One hundred ninety- two patients were evaluable of microbiologic efficacy. The overall bacteriologic eradication rates by pathogen were 94% and 87% for levoflaxacin and cefaclor, respectively. Levofloxacin eradicated 100% of Haemophilus influenzae, 95% of Moraxella catarrhalis, and 90% of Streptococcus pneumoniae organisms vs. 71%, 100%, and 86%, respectively, for cefaclor. Clinical success was observed in 92% of the patients in both groups. Drug-related adverse events were reported in 7% and 5% of patients, respectively, with gastrointestinal adverse events being the most common. These results indicate that once a day dosing of levofloxacin (500 mgg) is as effective and well tolerated as three-times-per-day dosing of cefaclor (250 mgg) in the treatment of patients with ABECB.
UR - http://www.scopus.com/inward/record.url?scp=0031934272&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031934272&partnerID=8YFLogxK
U2 - 10.1097/00019048-199802000-00009
DO - 10.1097/00019048-199802000-00009
M3 - Article
AN - SCOPUS:0031934272
SN - 1056-9103
VL - 7
SP - 101
EP - 109
JO - Infectious Diseases in Clinical Practice
JF - Infectious Diseases in Clinical Practice
IS - 2
ER -